Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment

Table 2 Frequency of the autoantibodies assessed before therapy and at different times after initiation of infliximab treatment

Antibody	Positivity (n [%])				P value^a
	Before therapy	From start of infliximab treatment
		30 weeks	54 weeks	78 weeks
ANA	15/30 (50)	21/30 (70)	23/30 (76.7)	24/30 (80)	0.0292
Anti-dsDNA (ELISA)	2/30 (6.7)	3/30 (10)	5/30 (16.7)	0/30 (0)	0.4915
Anti-dsDNA (IIF)	1/30 (3.3)	1/30 (3.3)	2/3 (6.7)	1/30 (3.3)	-
Anti-ENA^b	3/30 (10)	4/30 (13.3)	4/30 (13.3)	4/30 (13.3)	0.999
aCL IgG	0/30 (0)	1/30 (3.3)	2/30 (6.7)	2/30 (6.7)	0.4915
aCL IgM	0/30 (0)	1/30 (3.3)	2/30 (6.7)	3/30 (10)	0.2373
ANCA	0/30 (0)	0/30 (0)	0/30 (0)	0/30 (0)	-
RF	26/30 (86.7)	27/30 (90)	25/30 (83.3)	24/30 (80)	0.7306
Anti-CCP	25/30 (83.3)	22/30 (73.3)	22/30 (73.3)	25/30 (83.3)	-
EMA (IIF)	0/30 (0)	0/30 (0)	0/30 (0)	0/30 (0)	-

^aComparison between 0 and 78 weeks. ^bOnly anti-SSA(Ro) reactivity was found. ACL, anticardiolipin; ANA, antinuclear antibody; ANCA, antineutrophil cytoplasmic antibody; CCP, cyclic citrullinated peptide; DAS 28, Disease Activity Score; ds, double-stranded; ELISA, enzyme-linked immunosorbent assay; EMA, antiendomysial antibody; ENA, extractable nuclear antigen; IIF, indirect immunofluorescence; RF, rheumatoid factor.

ISSN: 1478-6362